CCM
ITCI

Consonance Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Consonance Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,654,600
Closed -$25.4M – 39
2020
Q1 		$25.4M Sell
1,654,600
-320,400
-16% -$6.96M 1.89% 21
2019
Q4 		$67.8M Buy
1,975,000
+1,955,000
+9,775% +$23.5M 4.14% 9
2019
Q3 		$149K Buy
+20,000
New +$192K 0.01% 30

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Consonance Capital Management's ITCI Position: Q2 2020 in Review

Consonance Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2020, closing a stake of 1,654,600 shares — an estimated $25.4M sold.

Consonance Capital Management first reported a position in ITCI in Q3 2019 and held it in 3 quarters. The position peaked at $67.8M in Q4 2019. 149 funds tracked by Wall St. Rank hold ITCI as of Q2 2020.

  • Consonance Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 1,654,600 Intra-Cellular Therapies Inc. shares in Q2 2020, an estimated $25.4M.
  • Consonance Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2019 and held it in 3 quarters.
  • Consonance Capital Management's Intra-Cellular Therapies Inc. position peaked at $67.8M in Q4 2019.
  • 149 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.